Phase II study of IMO-2125 in combination with pembrolizumab in patients with non-small-cell-lung-cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Tilsotolimod (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Aug 2018 According to the Idera Pharmaceuticals media release, The principal investigator is Arafat Tfayli, MD, Professor of Clinical Medicine, Director of Hematology/Oncology Fellowship Program at the American University of Beirut Medical Center (AUBMC), Lebanon.
- 23 Apr 2018 New trial record
- 16 Apr 2018 According to the Idera Pharmaceuticals media release, Pillar Partners will provide funding and Idera will provide drug IMO-2125 to conduct this trial. Arafat Tfayli is the principal investigator for this investigator initiated trial and this trial is expected to initiate before the end of 2018.